Australian immuno-oncology company Imugene (ASX:IMU) has moved to accelerate development of its lead cancer therapy after reporting encouraging clinical results, while launching a capital raising to fund the next phase of trials. …
Imugene launches $20 million capital raise to fund expansion of Azer Cel trials
March 12, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech -
Cell therapy company Mesoblast names executive to guide clinical development and medical affairs
March 12, 2026 - - Australian Biotech -
Patrys moves toward first human trial for injectable delirium therapy
March 12, 2026 - - Australian Biotech -
Imugene launches $20 million capital raise to fund expansion of Azer Cel trials
March 12, 2026 - - Australian Biotech -
Australia at a crossroads as the nuclear medicine revolution gathers pace
March 12, 2026 - - Latest News -
New Zealand confirms earlier access to breakthrough cystic fibrosis medicines
March 12, 2026 - - Latest News -
Fundraising racing towards total target as teams and participants prepare to climb
March 11, 2026 - - Latest News